Larimar Therapeutics (LRMR) Cash from Investing Activities (2013 - 2025)

Larimar Therapeutics' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at $18.8 million for Q2 2025.

• Quarterly Cash from Investing Activities rose 129.68% year-over-year to $18.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $79.8 million (up 144.09% YoY) and the FY2025 annual result came in at $100.3 million, up 217.48% from the prior year.
• Cash from Investing Activities was $18.8 million for Q2 2025 at Larimar Therapeutics, up from $14.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $92.2 million in Q1 2023 and bottomed at -$68.4 million in Q1 2024.
• A 5-year average of -$3.1 million and a median of $1.3 million in 2021 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2021 — Cash from Investing Activities slumped 84787.5% — and 2024, when it surged 830.2%.
• Larimar Therapeutics' Cash from Investing Activities stood at $6.5 million in 2021, then slumped by 904.84% to -$52.2 million in 2022, then soared by 94.97% to -$2.6 million in 2023, then jumped by 830.2% to $19.2 million in 2024, then declined by 1.85% to $18.8 million in 2025.
• Business Quant data shows LRMR's Cash from Investing Activities at $18.8 million in Q2 2025, $14.4 million in Q1 2025, and $19.2 million in Q4 2024.